摘要
目的:观察2型糖尿病肾病患者血清LP(a)水平变化,分析LP(a)水平与肾损害程度的相关性,并探讨氟伐他汀对LP(a)的影响及防治糖尿病肾病进展中的意义。方法:选择192例不同尿微量清蛋白排泄率的2型糖尿病患者和50例对照者,测定其血清中TG、TC、HDL-C、VLD-C,LP(a)的水平及Scr、UAER。分析血清Lp(a)质量浓度变化与DN进展之间的关系。同时测定氟伐他汀在早期糖尿病肾病组中治疗后上述指标。结果:2型糖尿病肾病患者LP(a)随肾功能的减退呈升高趋势,两者呈正相关(P<0.05),而血糖与肾损害程度无明显相关性;氟伐他丁能降低糖尿病肾病患者LP(a)水平而对血糖水平无影响。结论:LP(a)水平与2型糖尿病肾病肾损害有关,可作为糖尿病肾病的危险性预测因素,氟伐他丁能下调LP(a)水平,具有肾脏保护作用。
Objective：To investigate lipoprotein（a） levels diabetic nephropathy（DN）,and to analyze the relationship between LP（a） levels and evolution of DN.To explore the effect of fluvastatin on lipoprotein（a） and the significance of lowering the serum LP（a） in prevention of the progression of DN.Methods：Serum TG,TC,HDL-C,LDL-C,LP（a）,Scr and UAER in 192 patients with diabetes of different urinary albumin excretion rate（UAER） and 50 healthy subjects were detected,and the results in different groups were statistically analyzed.The above-mentioned index were detected after the treatment of fluvastatin in the group of EDN.Results：There were positive in accord with degree of kidney damage（P0.05）.FBG level correlated negatively with kidney damage.Fluvastatin could lower the serum LP（a） and was no effect on serum glucose.Conclusion：LP（a）levels is related to the degree of diabetic nephropathy.LP（a） is a promising predictive factor for the diagnosis of earlier nephropathy.Fluvataina can down regulation LP（a）,has a role in the prevention and freatment of diabetic nephropathy.
出处
《中国当代医药》
2010年第36期11-13,共3页
China Modern Medicine
